There is one clinical trial.
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
Description: Considering healing and/or reducing symptoms and severity of initial presentation
Measure: Illness development Time: 7 daysDescription: Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care
Measure: Reduction of need ICU admission Time: 14 daysDescription: Preventing patient from dying
Measure: Reduction of mortality rate Time: 30 daysDescription: potential need of reducing or augmenting doses
Measure: Optimyzing doses of drugs used in the clinical trial Time: 14 daysDescription: Outcome of adverse effects to one or more drugs used in the clinical trial
Measure: Adverse effects Time: 14 days